Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2021-03-19 Annual Report
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Samsung Pharm Co., Ltd. for the fiscal year 2020 (Jan 1, 2020 to Dec 31, 2020). In the South Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the US 10-K, serving as the comprehensive annual report containing financial statements, business operations, and governance information. It is not an announcement or a summary, but the full statutory filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange. FY 2020
2021-03-19 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samsung Pharm regarding a significant change in revenue or profit/loss structure (30% or more). It provides key financial highlights (revenue, operating profit, net income) and explains the reasons for these changes. While it contains financial data, it is an initial announcement of financial results rather than a full annual report or audited financial statement, as explicitly stated by the disclaimer that figures may change upon final audit. Therefore, it fits the definition of an Earnings Release (ER). FY 2020
2021-03-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samsung Pharmaceutical. It outlines the date, location, and agenda items (financial statements, director compensation, etc.) for the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2021-03-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Samsung Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including financial statement approval, director/auditor compensation limits, and other corporate governance items. It also includes detailed proxy information and voting instructions. This document is a standard proxy statement/information circular provided to shareholders prior to an AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2021-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often associated with the DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the agenda, financial statements, and details on how to exercise voting rights. This falls under the category of Proxy Solicitation & Information Statement (PSI).
2021-03-12 Korean
주요사항보고서(유형자산양도결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the decision to dispose of tangible assets (유형자산 양도 결정). This is a specific regulatory disclosure required for material corporate events. Since it does not fit into categories like M&A (TAR) or Share Issues (SHA), and is a formal regulatory filing for a material event, it falls under the 'Regulatory Filings' category.
2021-02-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.